Pfizer Inc. (NYSE: PFE, "Pfizer") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.
"IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoing battle against infectious diseases," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. "At Pfizer, we continue to prioritize innovation and rigorous data generation through clinical studies and real-world analysis supporting the vaccines and therapeutics for our infectious disease pipeline."
Presentations will include research from Pfizer's diverse infectious disease portfolio, including COVID-19, respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, meningococcal disease, and other serious bacterial and viral infections. Details for the oral and poster presentations are below:
Title/Abstract Number |
Presenting Name/Type |
Date/Time (ET) |
Location |
ORAL & LATE-BREAKING PRESENTATIONS |
|||
Attitudes about COVID and Community Engagement with Patients (ACCEPt): Global Survey Reveals the Ongoing Impact of Long COVID-19 on Medically Vulnerable Populations, Five Years On |
R Paredes |
Oct 22 4:15 - 4:30PM |
B211-B212 |
Effectiveness of the JN.1-adapted BNT162b2 COVID-19 Vaccine in High-Risk Groups against Hospitalization in Europe: A Test-Negative Case-Control using the id.DRIVE Platform |
H Volkman |
Oct 21 1:45 - 3:00PM |
B401-B402 |
Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Lower Respiratory Tract Disease (LRTD) Hospitalizations and Emergency Department Admissions over Two RSV Seasons-Kaiser Permanente of Southern California (KPSC), October 2023-April 2025 |
S Tartof |
Oct 20 3:15 - 4:30PM |
B401-B402 |
Immunosuppression and RSV Prefusion F Protein Vaccine Effectiveness in Older Adults: A Prespecified sub analysis from the DAN-RSV Trial |
A Jensen |
Oct 20 3:15 - 4:30PM |
B401-B402 |
POSTER PRESENTATIONS |
|||
COVID-19 |
|||
COVID-19 vaccine uptake in children aged 1 - 4 years from state vaccine registry data through March 2024 |
T Ahi |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Public Health and Economic Impact of Increased Uptake of an Additional Dose of Pfizer-BioNTech KP.2-Adapted COVID-19 Vaccine, 2024-2025 Formula, Among US Adults ≥ 65 Years of Age |
A Yehoshua |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Physician Perceptions and Decision-Making Factors in Prescribing COVID-19 Antivirals: Qualitative Research Findings |
M Fernandez |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Ibuzatrelvir Potently Reduced Viral RNA Levels Despite the High Rate of Anti-S Seropositivity: a Post Hoc Analysis of Serology in the Phase 2b Study in Adults Without Risk Factors for Severe COVID-19 |
JH Kim |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Inpatient Burden of Respiratory Syncytial Virus, COVID-19, or Influenza in the United States Among Children < 5 Years of Age |
K Andersen |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Severity of Omicron COVID-19 variants: a global systematic literature review |
D Malhotra |
Oct 22 12:15 PM |
Poster Hall B4-5 |
COVID-19 Case Attack Rate Differences by Vaccination Status and Vaccine Effectiveness among US Nursing Home Residents, October 5, 2024 to January 5, 2025 |
F Khan |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Invasive Group B Streptococcus (GBS) |
|||
Invasive Group B Streptococcus among hospitalized pregnant and postpartum women, 2016-2024: a Unites States database study |
S Willis |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Long-Term Healthcare Utilization and Expenditures for Infants with Invasive Bacterial Infections During Birth Hospitalizations |
K Schley |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Lyme Disease |
|||
Risk Perception and Communication about Lyme Disease Prevention by Healthcare providers: A Mixed-Methods Study |
N Patel |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Gestational Lyme disease incidence and pregnancy-related outcomes among women in the United States, 2015-2024 |
S Willis |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Healthcare Costs Associated With Lyme Disease Among Medicare Fee-for-Service Beneficiaries in the United States: A Retrospective Claims-Based Study |
H Yu |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Meningococcal Disease |
|||
Need for Broad Protection Against Invasive Meningococcal Disease Among US College Students |
J Presa |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Characterization of Factor H Binding Protein Expression for Neisseria meningitidis Serogroup B Isolates, 2015-2022 |
K Weiss |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Clinical Development of MenABCWY (PenbrayaTM), a Broadly Protective Pentavalent Meningococcal Vaccine |
L Zoloras |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Utility of the Pentavalent MenABCWY Meningococcal Vaccine (PenbrayaTM) Within Alternative US Meningococcal Vaccination Schedules |
J Presa |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Ten-year retrospective review of medical records at five hospitals in the United States highlights the potential for under-detection of invasive meningococcal disease |
F Angulo |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Awareness, Attitudes and Perceptions of Meningococcal Vaccines among Caregivers of Adolescents in the United States |
J Presa |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Pneumococcal Disease |
|||
Re-evaluating economic & health impact of PCV20 in adults using real-world effectiveness data |
J Vietri |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Invasive pneumococcal pneumonia: is bacteremia the appropriate indication of severity? |
P Peyrani |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Variability in Case-Ascertainment Methodology and Rates of Adult Invasive Pneumococcal Disease using a US Healthcare Claims Database |
A Miles |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Temporal Trends in Rates of Hospitalized Pneumonia among US Adults and Residual Disparities by Race and Socioeconomic Status |
A Miles |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Demographic and Clinical Characteristics, by Pneumococcal Serotype, of Adults Hospitalized with Community Acquired Pneumonia in the US |
L Grant |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Differences in invasive pneumococcal disease clinical presentations and serotype distribution among children with and without underlying risk factors |
K Hulten |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Nasopharyngeal Colonization in South Texas Children Less Than 6 Years of Age With or Without Lower Respiratory Tract Infections |
K Hulten |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults 65-74, 75-84, and ≥85 years of age in the United States |
A Miles |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Uptake and Series Completion with Pneumococcal Conjugate Vaccine by Social Determinants of Health among Children in the United States |
A Miles |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Influenza |
|||
Symptom Burden During the First Week of Acute Influenza Infection Among US Adults: An Interim Analysis of a Nationwide Prospective Study during the 2024/25 Season |
T Hu |
Oct 20 12:15 PM |
Poster Hall B4-5 |
The Burden of Influenza on Health-Related Quality of Life and Work Productivity During the First Week of infection Among US Adults: An Interim Analysis of a Nationwide Prospective Study |
T Hu |
Oct 22 12:15 PM |
Poster Hall B4-5 |
The Socioeconomic Value of Adult Respiratory Vaccination in the United States: A Benefit-Cost Analysis |
T Hu |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Respiratory Syncytial Virus (RSV) |
|||
How do recent population-level RSVpreF vaccine impact results from the United Kingdom relate to previously reported vaccine effectiveness results? |
N Aliabadi |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Bivalent RSV Prefusion F-Based Subunit Vaccine Recipients with Chronic Kidney Disease Achieved High Neutralizing Titers One Month After Vaccination |
F Rahman |
F Oct 21 12:15 PM |
Poster Hall B4-5 |
Immunogenicity and Safety of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Non-Pregnant HIV Infected Older Adults |
T Mikati |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-Controlled Case Series Analysis |
C Liang |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Time to Testing, Diagnosis, and Hospitalization Among Pediatric and Adult Patients with RSV in Two Seasons: A Real-World Data Analysis using Electronic Health Records in US |
W Tang |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Time-Series Model Estimation of RSV-Attributable Respiratory Hospitalizations and Mortality in Adults in Finland |
C Liang |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Burden of Hospitalizations Due to Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations |
A Tippett |
Oct 20 12:15 PM |
Poster Hall B4-5 |
What if Adult RSV Vaccine Uptake in the US was High Like in Scotland? Missed Opportunities to Reduce Public Health and Economic Burden of RSV |
R Sato |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Strategies to promote adult vaccination against respiratory pathogens: a narrative literature review |
E Williams |
Oct 21 12:15 PM |
Poster Hall B4-5 |
Attributes of Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus (RSV): Results of a Systematic Literature Review |
K Date |
Oct 20 12:15 PM |
Poster Hall B4-5 |
RSV Signs and Symptoms at Time of Hospitalization among Pediatric and Adult Population with RSV in Two Seasons: A Real-World Data Analysis using Electronic Health Records in US |
W Tang |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Tick-Borne Encephalitis (TBE) |
|||
Tick-borne encephalitis (TBE) in international travelers and TBE vaccine recommendations for travelers to Europe |
F Angulo |
Oct 20 12:15 PM |
Poster Hall B4-5 |
Prescribing Information for Pfizer Medicines
Please see full Prescribing Information for ABRYSVO® (Respiratory Syncytial Virus Vaccine) or visit https://abrysvoadult.pfizerpro.com.
Please see full Prescribing Information for COMIRNATY® (COVID-19 Vaccine, mRNA) or visit https://comirnatyhcp.com.
Please see full Prescribing Information including BOXED WARNING for PAXLOVIDTM (Nirmatrelvir and Ritonavir) or visit https://paxlovid.pfizerpro.com.
Please see full Prescribing Information for PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine) or visit https://prevnar20.pfizerpro.com.
Please see full Prescribing Information for PREVNAR 13®(Pneumococcal 13-valent Conjugate Vaccine).
Please see full Prescribing Information for PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine) or visit https://penbraya.pfizerpro.com.
Please see full Prescribing Information for TRUMENBA® (Meningococcal Group B Vaccine) or visit https://trumenba.pfizerpro.com.
Please see full Prescribing Information for TICOVAC™.
